12.08MMarket Cap-0.02P/E (TTM)
3.450High3.060Low72.13KVolume3.410Open3.360Pre Close234.78KTurnover3.82%Turnover RatioLossP/E (Static)3.65MShares27.50052wk High-5.94P/B6.25MFloat Cap3.06052wk Low--Dividend TTM1.89MShs Float1751062.500Historical High--Div YieldTTM11.61%Amplitude3.060Historical Low3.254Avg Price1Lot Size
Traws Pharma Stock Forum
Traws Pharma Announces Completion of Phase I Studies with Tivoxavir Marboxil, a Single Dose Oral Investigational Drug for the Treatment and Prevention of H5N1 Bird Flu
Thursday, 23rd January at 7:00 am
Phase I completed in healthy volunteers with pharmacokinetic data supporting dosing for both therapeutic and further development for bird flu prevention
NEWTOWN, Pa., Jan. 23, 2025 /PRNewswire/ -- Traws Pharma, Inc. (NASDAQ: TRAW) ("Traws Pharma", "Traws" or "the Compan...
Traws Pharma Announces Completion of Phase I Studies With Tivoxavir Marboxil, a Single Dose Oral Investigational Drug for the Treatment and Prevention of H5N1 Bird Flu
📊⚡️📊
$SEALSQ Corp (LAES.US)$ today
One state leads country in human bird flu with nearly 40 confirmed cases | Fox News
No comment yet